Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases

Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Jia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu

Clin Mol Hepatol. 2024;30(1):16-36. Published online October 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0315

View: 3104 Download: 249 Crossref: 1

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 11720 Download: 987 Web of Science: 43 Crossref: 57

Editorial

Adding to the confusion in more than just the name

Jacob George

Clin Mol Hepatol. 2023;29(4):973-976. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0367

View: 1422 Download: 62 Web of Science: 3 Crossref: 4

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials

Ming-Lun Yeh, Ming-Lung Yu

Clin Mol Hepatol. 2023;29(4):969-972. Published online September 18, 2023

DOI: https://doi.org/10.3350/cmh.2023.0359

View: 1878 Download: 143 Web of Science: 3 Crossref: 4

Original Article

Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone Strasser, Jacob George

Received February 15, 2024 Accepted April 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109 [Accepted]

View: 462 Download: 55

1 |

Viewed By 5594	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4810	MAFLD: How is it different from NAFLD?
Viewed By 4552	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3718	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3702	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Search